A Phase 1, Single-Centre Study Evaluating the Safety, Tolerability and Pharmacokinetics of Single and Multiple Escalating Doses of Intravenous Formulation of Solithromycin (CEM-101) In Healthy Adult Subjects.

Trial Profile

A Phase 1, Single-Centre Study Evaluating the Safety, Tolerability and Pharmacokinetics of Single and Multiple Escalating Doses of Intravenous Formulation of Solithromycin (CEM-101) In Healthy Adult Subjects.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs Solithromycin (Primary)
  • Indications Bacterial infections; Community-acquired pneumonia
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 05 Jun 2017 Results of the single ascending dose portion (n=42), presented at the ASM Microbe 2017.
    • 09 Aug 2012 Cempra expects to complete this trial in the second half of 2012.
    • 10 May 2011 Results presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top